SEC Form 424B3 filed by Tevogen Bio Holdings Inc.
$TVGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company's determination to advance its mission of developing accessible, life-saving therapeutics. The company recently announced significant progress through its third quarter financial results for 2024, including, reduction of a net loss by $52.5 million, elimination of nearly
Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023, respectively.Significantly improved financial position by eliminating nearly all of its liabilities; reported $10.5 million as of September 30, 2024, and $99.9 million as of December 31, 2023.$10 billion+, representing Tevogen's IP and product assets based on internal discounted cash flow models, is not reflected on the company balance sheet. Similarly, Tevogen's AI assets, a critical component of its innovation platform, remain unreported on company balance sheet.Sufficient available capital to fund operations fo
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.Tevogen's success would not be possible without its passionate team united by a common vision.Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution.Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share which could provide the company with over $200 million. WARREN, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NAS
424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)
10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)
NT 10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)
WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP. The shares of Series C Preferred Stock will have a 7.5% dividend per year, accruing and payable quarterly. The Series C Preferred Stock is convertible into shares of common stock after 6 months at the election of the holder, and callable by Tevogen for redemption after 5 years at Tevogen's e
WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. Tevogen's reported $5.1 million net cash used in operating activities and $33.0 million in non-cash expenses for the six months ending June 30, 2024. The key non-cash expense items included $30.5 million in stock-based compensation expenses. The Com
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
Tevogen Bio Holding Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, today released a letter to stockholders highlighting recent achievements, growth plans, and consideration of a potential share buyback.
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen's ExacTcell™ platform is designed to address current cost, and patient accessibility challengesExacTcell's first product consists of single HLA restricted, off-the-shelf, genetically unmodified T cellsBroad application potential spanning cancer, infectious diseases, and neurological disordersExacTcell platform produced hundreds of doses from a single donor, facilitating cost reduction WARREN, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio Holding Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotec
WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is pleased to announce the appointment of Anthony Tarantino as its new Patient Advocate. Tarantino, a well-known leader in firefighter safety and community advocacy, brings extensive experience in representing and supporting high-risk groups, including first responders. Anthony Tarantino previously served as President of the Newark Fire Officers Union and Legislative Vice President of the Professional Firefighters As
WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio ("Tevogen") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Salesforce CEO Marc Benioff on receiving the Yale Legend in Leadership Award for highlighting that business success must coexist with social prosperity at the bi-annual CEO Summit. The Yale Legend in Leadership Award was created 35 years ago to honor current and former CEOs who serve as living legends to inspire chief executives across industries, sectors, and nations. "I share Marc's belief
WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membershi
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)
SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)
SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)